Synlogic says preclinical data support advancement of IO program candidates
Synlogic announced the presentation of preclinical data from its Synthetic Biotic immuno-oncology program at the Keystone Symposium Lymphocytes and their Roles in Cancer. "These data provide compelling, early scientific evidence supporting the development of our Synthetic Biotic medicines as potential novel immunotherapeutic agents for the treatment of various cancers. The results demonstrate that we can design Synthetic Biotic medicines that dramatically modulate the tumor microenvironment, by generating potent and efficacious antitumor immunity, turning what is known as a "cold" tumor "hot" and resulting in greatly enhanced response rates. Our Synthetic Biotic medicines can be administered by intratumoral injection enabling achievement of these beneficial effects locally and without systemic toxicity. Moreover, we can engineer additional activities into this new class of living medicines that enhance and sustain the anti-tumor response. In the coming year we intend to advance these IO program candidates into IND-enabling studies," said J.C. Gutierrez-Ramos, Ph.D., Synlogic's president and CEO.